On June 4, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and Akari’s positioning within the evolving ADC landscape.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the segment, Mr. Gaslightwala reflects on the accelerating pace of innovation across oncology and the growing industry focus on difficult-to-treat, genetically defined cancers, particularly KRAS-driven tumors such as pancreatic, lung and colon cancers where significant unmet need remains today.
Mr. Gaslightwala also discusses the continued momentum surrounding ADC development and what he believes represents the industry’s transition toward "ADC 2.0," driven by increasing demand for differentiated payload technologies capable of overcoming limitations associated with existing Top1 and MMAE payload classes.
The discussion highlights emerging clinical data presented at ASCO (Free ASCO Whitepaper) suggesting limited efficacy when patients receive sequential ADC therapies utilizing the same payload class following relapse, reinforcing the growing need for novel payload approaches across the ADC landscape.
As part of the CEO Corner, Mr. Gaslightwala discusses Akari’s proprietary PH1 spliceosome-modulating payload platform and why the Company believes its differentiated mechanism may potentially help address resistance challenges observed with current ADC approaches while expanding therapeutic applicability across multiple difficult-to-treat solid tumors.
The segment also highlights Akari’s first accepted ASCO (Free ASCO Whitepaper) abstract featuring preclinical data demonstrating combination synergy between the PH1 ADC payload and a KRAS inhibitor in KRAS-mutated pancreatic cancer models, further supporting the potential applicability of Akari’s novel payload platform within the rapidly evolving KRAS therapy landscape.
In addition, Mr. Gaslightwala outlined several anticipated milestones investors should monitor throughout the remainder of 2026, including continued advancement of Akari’s PH1 spliceosome-modulating payload platform and the Company’s planned initiation of its Phase 1 first-in-human clinical trial for its lead development candidate AKTX-101which is expected by mid-2027.
(Press release, Akari Therapeutics, JUN 4, 2026, View Source [SID1234666437])